Selective Serotonin Reuptake Inhibitors (SSRIs) — Complete Teaching Guide

---

PART 1 — HISTORY

---

PART 2 — PSYCHOPHARMACOLOGY & MECHANISM OF ACTION

The Core Mechanism: SERT Inhibition

The Five-Step Mechanism of Action (Stahl)

1. Acute (hours): SSRI blocks SERT → serotonin accumulates at axon terminals AND at somatodendritic areas near the cell body. The cell body area has 5-HT1A autoreceptors that act as a brake — high local 5-HT activates them and inhibits neuronal firing.
2. Early (days): Because 5-HT1A autoreceptors are being continuously stimulated by elevated 5-HT, they begin to desensitize (downregulate). The brakes start releasing.
3. Intermediate (1–2 weeks): As somatodendritic 5-HT1A autoreceptors downregulate, the inhibition on neuronal firing lifts → impulse flow resumes normally.
4. Delayed (2–4 weeks): With normal impulse flow restored, serotonin is now released at axon terminals → synaptic 5-HT rises at target regions. This is when therapeutic effects begin. The delay explains why SSRIs don't work immediately.
5. Later (4–8 weeks): Postsynaptic 5-HT receptors downregulate as well → tolerance to side effects develops, and sustained clinical response is established.

Psychodynamic Considerations

---

PART 3 — PHARMACOKINETICS

Comparison Table

• Fluoxetine has the longest combined half-life (~7 days including norfluoxetine). This means: (a) no significant discontinuation syndrome, (b) no need for taper on stopping, (c) requires 5-week washout before starting an MAOI.
• Paroxetine has the shortest half-life and is an autoinhibitor of its own metabolism (CYP2D6) — even small dose reductions cause disproportionately steep plasma level drops, causing the worst discontinuation syndrome of all SSRIs.
• Escitalopram has minimal CYP interactions — best choice when polypharmacy is a concern (Harrison's).
• All SSRIs achieve steady-state in ~5 half-lives. For fluoxetine this takes ~5 weeks.
• All are extensively protein-bound — less affected by renal disease; dose-adjust in severe hepatic impairment.
• Food does not significantly affect absorption of any SSRI.

CYP Interactions — Clinical Implications

Tamoxifen note (2025 update): CYP2D6 inhibitors (fluoxetine, paroxetine) theoretically reduce conversion of tamoxifen to endoxifen. However, a 2022 systematic review of ~100,000 breast cancer patients found no adverse oncologic outcomes from concurrent use; updated guidelines recommend not switching antidepressants solely for this reason.

---

PART 4 — INDICATIONS

FDA-Approved Indications (US) by Drug

Off-Label Uses (well-supported)

• Generalized anxiety disorder (all SSRIs)
• Body dysmorphic disorder
• Trichotillomania & skin-picking disorder
• Premenstrual dysphoric disorder (low-dose intermittent)
• Fibromyalgia (fluoxetine)
• Premature ejaculation (paroxetine — evidence-based off-label)
• Irritable bowel syndrome
• Hot flashes (menopause-related)
• Autism-associated repetitive behaviors

---

PART 5 — CLINICAL GUIDELINES & TREATMENT ALGORITHM

First-Line Selection (2024–2025 Guidelines)

1. Start with escitalopram or sertraline — best efficacy-tolerability balance, fewest drug interactions, most evidence.
2. Alternatives: fluoxetine (if activating properties needed, eating disorders, pregnancy [most data]), paroxetine (if sedation needed, though avoid in elderly), citalopram (avoid >40 mg due to QTc).
3. Paroxetine is least preferred for: elderly patients, pregnancy (neonatal withdrawal), patients likely to need future dose adjustments.

Step-Care Algorithm

Step 1: Start SSRI (escitalopram/sertraline preferred)
         ↓  4–8 weeks at therapeutic dose
Step 2: Inadequate response?
         → Optimize dose (go to maximum tolerated)
         → 4 more weeks
         ↓
Step 3: Still inadequate?
         → Switch: SSRI → SNRI (or different SSRI)
         → Or Augment: lithium, aripiprazole, quetiapine, T3
         ↓
Step 4: Treatment-resistant (≥2 adequate trials failed)
         → ECT, ketamine/esketamine, TMS
         → Consider MAOIs (specialist)

---

PART 6 — DOSING & FORMULATIONS

Standard Doses

Titration Principles

• Start low, go slow — especially in anxiety disorders (initial activation effect can worsen anxiety)
• Increase dose after 2–4 weeks if tolerated but subtherapeutic response
• Allow 4–8 weeks at therapeutic dose before declaring a trial failed
• In elderly: start at half the adult starting dose; titrate more slowly
• In children/adolescents: fluoxetine has the most RCT evidence; start at 10 mg

---

PART 7 — THE SIX SSRIs INDIVIDUALLY

---

1. FLUOXETINE (Prozac)

• Most activating → best for depression with hypersomnia, psychomotor retardation, fatigue, apathy
• May worsen agitation and insomnia in anxious patients
• Only SSRI approved for bulimia nervosa (higher dose, 60 mg)
• Approved for depression + bipolar when combined with olanzapine (Symbyax)

---

2. SERTRALINE (Zoloft)

• Best overall efficacy-tolerability balance — most broadly prescribed SSRI worldwide
• Lowest risk of drug-drug interactions of the commonly used SSRIs (Harrison's)
• GI side effects (diarrhea) slightly more common than others
• DAT inhibition may improve motivation and drive at higher doses
• Sigma-1 binding: potential anxiolytic properties, mood stabilization

---

3. PAROXETINE (Paxil, Paxil CR)

• Most anticholinergic SSRI → dry mouth, constipation, urinary hesitancy, blurred vision, sedation
• NET inhibition → slightly more noradrenergic than other SSRIs → possibly more robust for anxiety
• NOS inhibition → contributes to sexual dysfunction and premature ejaculation treatment
• Most sedating SSRI → useful for patients with insomnia-predominant depression
• Most problematic for discontinuation syndrome (shortest half-life + autoinhibition of CYP2D6)

---

4. FLUVOXAMINE (Luvox)

• Not FDA-approved for MDD in adults (approved for OCD and social anxiety)
• Sigma-1 receptor agonism: anxiolytic, antipsychotic-like, neuroprotective effects; may confer unique benefits in autism, OCD, schizophrenia
• OCD drug of first choice in children in some guidelines
• Most significant CYP interactions of all SSRIs (inhibits 1A2, 2C9, 3A4) → use caution with clozapine, olanzapine (can markedly raise levels), theophylline, warfarin
• Must be given twice daily (no once-daily formulation except CR capsule)
• COVID-19 note: Fluvoxamine gained attention in 2020–2022 (TOGETHER trial) for possible benefit in early COVID via sigma-1 agonism; results were modest and not definitive

---

5. CITALOPRAM (Celexa)

• Cleanest pharmacological profile of the original SSRIs — least receptor promiscuity
• Minimal CYP interactions → good for elderly and polypharmacy patients
• Critical safety issue: QTc prolongation
  • FDA black box warning (2012): maximum dose 40 mg/day (20 mg/day in elderly, hepatic impairment, or with CYP2C19 inhibitors like omeprazole)
  • Dose-dependent QTc prolongation → risk of torsades de pointes at higher doses
  • Monitor ECG in high-risk patients

---

6. ESCITALOPRAM (Lexapro) — The Quintessential SSRI

• Most selective SSRI — virtually no off-target effects
• Allosteric SERT binding: the S-enantiomer binds both the primary (orthosteric) and a secondary (allosteric) site on SERT — this may contribute to superior potency and possibly faster onset
• Minimal CYP inhibition → fewest drug interactions of all SSRIs (Harrison's)
• Best-tolerated SSRI in most comparative studies
• Consistently ranks #1 or #2 for efficacy in network meta-analyses (Cipriani 2018 Lancet)
• Effective across: MDD, GAD, social anxiety, panic disorder, OCD (off-label)

---

PART 8 — SIDE EFFECTS

Common Side Effects (All SSRIs)

• Dose reduction
• Drug holidays (2–3 times/month — not effective with fluoxetine due to long half-life)
• Switch to bupropion, mirtazapine, vortioxetine, or agomelatine (lower risk)
• Add sildenafil/tadalafil (evidence for men; limited for women)
• Add bupropion 100–150 mg/day (Maudsley)
• Amantadine 100 mg tid; buspirone 10 mg tid (Harrison's)

Serious/Rare Side Effects

---

PART 9 — SEROTONIN SYNDROME

Hunter Criteria for Diagnosis (requires ONE of):

1. Spontaneous clonus
2. Inducible clonus + agitation/diaphoresis
3. Ocular clonus + agitation/diaphoresis
4. Tremor + hyperreflexia
5. Hypertonia + temperature >38°C + clonus

Classic Triad:

• Neuromuscular: clonus (pathognomonic), hyperreflexia, tremor, myoclonus, rigidity
• Autonomic: hyperthermia, tachycardia, diaphoresis, hypertension
• Cognitive: agitation, confusion

Precipitating Combinations:

• SSRI + MAOI (most dangerous — avoid; requires washout)
• SSRI + tramadol, fentanyl, meperidine
• SSRI + triptans (theoretical; clinical risk debated)
• SSRI + linezolid (weak MAOI)
• SSRI + St. John's Wort
• SSRI + dextromethorphan
• SSRI + lithium (at toxic lithium levels)

Management:

1. Stop all serotonergic agents immediately
2. Supportive care: IV fluids, cooling
3. Benzodiazepines for agitation and seizures
4. Cyproheptadine 12 mg PO then 2 mg every 2 hrs (5-HT2A antagonist — antidote)
5. Severe cases: ICU, intubation, temperature control
6. Do NOT use physical restraints (cause hyperthermia)

---

PART 10 — OVERDOSE & TOXICITY

Clinical Features of Overdose:

• Tachycardia, mild hypotension, lethargy (especially with co-ingestants)
• Citalopram/escitalopram: most dangerous in overdose → dose-dependent QTc prolongation, QRS widening, seizures, torsades de pointes (even at overdoses of 600–1000 mg)
• Serotonin syndrome occurs in ~10% of overdoses

Treatment (Tintinalli):

• Observe 6 hours minimum; admit if: persistent tachycardia, altered mental status, citalopram/escitalopram ingestion, cardiac conduction abnormalities, serotonin syndrome features
• Gastric lavage, ipecac, whole-bowel irrigation: NOT recommended

---

PART 11 — SWITCHING STRATEGIES

Why Switch?

• Inadequate response after adequate trial (4–8 weeks at therapeutic dose)
• Intolerable side effects
• Drug interaction burden

Switching Principles

• Gradually taper down the first SSRI while gradually titrating up the new one
• Preferred for: paroxetine (due to discontinuation risk), patients sensitive to discontinuation

• Can usually do direct switch or cross-taper
• No washout required

• Always 2 weeks washout after stopping MAOI before starting any SSRI

Step-down titration for discontinuation (Maudsley Deprescribing Guidelines):

• Never abrupt discontinuation (except fluoxetine which can usually be stopped without taper)
• Paroxetine, venlafaxine: hyperbolic tapering — small percentage reductions over months
• Use liquid formulations or pill-cutting for micro-tapering
• Fluoxetine bridge: switch to fluoxetine (long half-life), stabilize, then taper fluoxetine slowly

---

PART 12 — DISCONTINUATION SYNDROME

FINISH Mnemonic:

• Flu-like symptoms (myalgias, sweating, nausea)
• Insomnia (vivid dreams, nightmares)
• Nausea/GI distress
• Imbalance/dizziness
• Sensory disturbances ("brain zaps" — electric shock sensations in head)
• Hyperactivation (anxiety, agitation, irritability)

Risk by Drug (Highest → Lowest):

1. Paroxetine (shortest half-life + autoinhibition = steepest drop)
2. Venlafaxine (short half-life, though technically SNRI)
3. Sertraline, citalopram, escitalopram (moderate)
4. Fluvoxamine
5. Fluoxetine (virtually none — long half-life provides self-taper)

Management:

• Prevention: Always taper; educate patients
• Mild: Reassurance; usually resolves 1–2 weeks
• Moderate-severe: Restart drug → stabilize → slower taper
• Fluoxetine bridge: Switching to fluoxetine, stabilizing, then tapering leverages its self-tapering property
• Kaplan & Sadock: movement symptoms (tremor, akathisia, parkinsonism) on discontinuation — manage akathisia with propranolol, anticholinergics, or benzodiazepines

---

PART 13 — CONTRAINDICATIONS

Absolute:

• Concurrent MAOI use (fatal serotonin syndrome risk)
• Known hypersensitivity to the drug

Relative / Caution:

---

PART 14 — SPECIAL POPULATIONS

Children & Adolescents:

• Fluoxetine: only SSRI FDA-approved for depression in children ≥8 years
• Fluoxetine and escitalopram: approved for adolescent depression
• All SSRIs: FDA black box warning — increased suicidal ideation in under-25s; monitor weekly initially
• OCD in children: sertraline, fluoxetine, fluvoxamine (all FDA-approved)
• CBT must accompany pharmacotherapy; do not use medication as sole treatment

Elderly:

• Start at half the adult dose; titrate slowly
• Preferred: escitalopram, sertraline (fewest interactions, no anticholinergic)
• Avoid paroxetine (Beers criteria — anticholinergic)
• Monitor: sodium (SIADH), falls (dizziness), QTc (avoid citalopram >20 mg)

Pregnancy:

• SSRIs are the most studied antidepressants in pregnancy
• Neonatal Adaptation Syndrome: transient in newborns — jitteriness, respiratory distress, poor feeding (especially paroxetine, venlafaxine); resolves in days; not a reason to withhold treatment
• Persistent Pulmonary Hypertension of Newborn (PPHN): weak signal with late-pregnancy SSRI exposure; absolute risk very low
• 2025 umbrella review (Fabiano et al., Mol Psychiatry): overall, SSRIs do not show strong teratogenic signal; risk of untreated depression > risk of SSRI exposure

Cardiac Disease:

• SADHART trial (2002): Sertraline safe in post-MI patients with depression; does not worsen cardiac outcomes
• ENRICHD trial: CBT + sertraline improved depression post-MI
• Preferred: sertraline, escitalopram (minimal CYP, no QTc at therapeutic doses)
• Avoid: citalopram >40 mg; paroxetine (anticholinergic, tachycardia)

---

PART 15 — EVIDENCE-BASED TRIALS

Landmark Studies

• Largest real-world antidepressant trial (n=4,041); used citalopram as first step
• 28% remission at step 1 (citalopram)
• Only ~33% remission after 4 steps → established treatment-resistance as a major clinical challenge
• Key message: most patients need more than one treatment step

• 522 trials, 116,477 patients, 21 antidepressants
• Escitalopram and sertraline had best combination of efficacy and acceptability
• All SSRIs were more efficacious than placebo
• Escitalopram ranked highest for both efficacy and tolerability

• SSRIs + SNRIs first-line for MDD, GAD, PTSD, OCD, panic disorder, social anxiety
• Augmentation with atypical antipsychotics (aripiprazole, quetiapine, brexpiprazole) for partial responders
• Level 1 evidence for escitalopram and sertraline in MDD

• Escitalopram vs. other antidepressants (Yin et al., BMC Psychiatry 2023, PMID 38001423): Escitalopram showed superior response and remission vs. several other antidepressants
• Panic disorder (Guaiana et al., Cochrane 2023, PMID 38014714): SSRIs and benzodiazepines both effective; SSRIs preferred long-term
• Hyponatremia risk (Gheysens et al., Eur Psychiatry 2024, PMID 38403888): SSRIs carry higher hyponatremia risk than other antidepressant classes
• SSRI safety in pregnancy (Fabiano et al., Mol Psychiatry 2025, PMID 39266712): low absolute teratogenic risk confirmed

---

PART 16 — RECENT ADVANCES (2023–2026)

1. Post-SSRI Sexual Dysfunction (PSSD): EMA and FDA have mandated label updates acknowledging PSSD as a real, potentially persistent adverse effect. Research ongoing into mechanisms (epigenetic? neurosteroid?).
2. Pharmacogenomics in SSRI prescribing: CYP2D6 and CYP2C19 genotyping is increasingly available; strong metabolizers may need higher doses; poor metabolizers risk toxicity. Not yet in routine guidelines but several countries are moving toward it.
3. Antidepressants and neuroplasticity: Beyond the monoamine hypothesis — antidepressants enhance BDNF signaling, promote neurogenesis in the hippocampus, and facilitate synaptic remodeling. This "neuroplasticity hypothesis" may explain why combining SSRIs with psychotherapy is synergistic.
4. Esketamine (Spravato) as augmentation / monotherapy: FDA approved esketamine as first monotherapy for treatment-resistant depression in January 2025 — not an SSRI, but defines the "after SSRI fails" landscape.
5. SSRI hyperbolic tapering (Maudsley Deprescribing Guidelines, 2022+): Evidence-based protocol for SSRI discontinuation using hyperbolic dose reductions (small % reductions of remaining dose) rather than linear steps — prevents protracted withdrawal. Widely adopted in UK.
6. Gepirone (Exxua) FDA approved 2023: A 5-HT1A partial agonist/5-HT2 antagonist antidepressant — new class but with serotonergic mechanism, positioned alongside SSRIs.
7. Digital phenotyping and prediction of SSRI response: Machine learning models using EEG biomarkers (e.g., frontal alpha asymmetry) and digital biomarkers to predict SSRI response before prescribing — early research stage.

---

QUICK REFERENCE SUMMARY TABLE

---

Sources

• Stahl's Essential Psychopharmacology, Cambridge University Press
• Harrison's Principles of Internal Medicine, 22nd ed. (McGraw-Hill, 2025)
• Kaplan & Sadock's Comprehensive Textbook of Psychiatry, 10th ed.
• The Maudsley Prescribing Guidelines in Psychiatry, 15th ed.
• Tintinalli's Emergency Medicine, 9th ed.
• Cipriani et al., Lancet 2018 (network meta-analysis, 21 antidepressants)
• Yin et al., BMC Psychiatry 2023 [PMID 38001423]
• Guaiana et al., Cochrane 2023 [PMID 38014714]
• Gheysens et al., Eur Psychiatry 2024 [PMID 38403888]
• Fabiano et al., Mol Psychiatry 2025 [PMID 39266712]